Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Clinical trial NCT07566156 · RECRUITING

Trial details

NCT number: NCT07566156
Sponsor: Astellas Pharma Global Development, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Urothelial Cancer Urinary Bladder Neoplasms

Start date: 2026-05-11
Primary completion: 2030-03-31
Enrollment: 390

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.